Disentangling placebo effects in the treatment of migraine

A new meta-analysis of placebo-controlled trials of calcitonin gene-related peptide (CGRP) antibodies for migraine has shown that the direct biological effects of these treatments beyond the effects of placebo are modest, raising questions about how the ‘true value’ of these and other drugs are asse...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Neurology Vol. 16; no. 12; pp. 657 - 658
Main Authors Loder, Elizabeth W., McGeeney, Brian
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.12.2020
Nature Publishing Group
Subjects
631/378/1689
692/617/375/1654
Cell receptors
Double-Blind Method
Drug therapy
Health aspects
Humans
Medicine
Medicine & Public Health
Migraine
Migraine Disorders - drug therapy
Monoclonal antibodies
Neurological research
Neurology
News & Views
news-and-views
Placebo Effect
United States
Online AccessGet full text

Cover

More Information
Summary:A new meta-analysis of placebo-controlled trials of calcitonin gene-related peptide (CGRP) antibodies for migraine has shown that the direct biological effects of these treatments beyond the effects of placebo are modest, raising questions about how the ‘true value’ of these and other drugs are assessed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Commentary-3
content type line 23
ISSN:1759-4758
1759-4766
1759-4766
DOI:10.1038/s41582-020-0406-7